Why the study?
Does triple antiplatelet therapy reduce enzymatic infarct size compared to dual antiplatelet therapy in patients with NSTE ACS planned for early catheterization?
Does triple antiplatelet therapy reduce enzymatic infarct size compared to dual antiplatelet therapy in patients with NSTE ACS planned for early catheterization?
Answers are grounded in this paper and cite their sources.
In patients with NSTE ACS planned for early catheterization, triple antiplatelet pre-treatment including tirofiban did not significantly reduce enzymatic infarct size but improved initial culprit vessel perfusion compared to dual antiplatelet therapy.
AIMS: To compare dual vs. triple antiplatelet pre-treatment in patients with non-ST-elevation acute coronary syndrome (NSTE ACS) who were planned for early catheterization. METHODS AND RESULTS: A total of 328 consecutive patients with NSTE ACS were included and were randomized to pre-treatment with dual (n = 166, aspirin, clopidogrel 600 mg) or triple antiplatelet therapy (n = 162, aspirin, clopidogrel 300 mg, and Tirofiban). The primary endpoint was enzymatic infarct size, defined as cumulative LDH release (LDHQ(48)). Initial TIMI flow of the culprit vessel was a pre-specified secondary endpoint. Angiography was performed in 98% of patients at a median of 23 h after admission. Enzymatic infarct size (median, 25-75%) was 166 (60-349) IU/L in the triple group compared with 193 (75-466) IU/L in the dual group (P = 0.2). Initial TIMI 3 flow of the culprit vessel was significantly more often observed after triple antiplatelet therapy (67 vs. 47%, P = 0.002). At 30 days follow-up, myocardial infarction (MI) occurred in 46% of patients in the triple antiplatelet group, compared with 57% in the dual antiplatelet group, P = 0.052. No significant difference in bleeding was present. CONCLUSION: This study showed that in patients with NSTE ACS, triple antiplatelet pre-treatment was associated with a non-significant reduction in enzymatic infarct size, a significantly better initial perfusion of the culprit vessel, and a trend towards a better survival without death or MI. Further, large-scale studies should be performed to find whether the beneficial trend in favour of triple antiplatelet pre-treatment can be reproduced.
No takes yet. Share an insight, caveat, or question.
Saman Rasoul (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: